Category: Intellectual property
-
Start-Up Licenses Children’s Myopia-Control Contact Lens
A start-up enterprise spun-off from Hong Kong Polytechnic University is licensing the technology for a customized contact lens that controls and prevents further myopia in children.
-
Institute, Company Partner on Implanted Neuro Device
A research center in Switzerland and medical engineering company in Germany are developing an implanted device to measure signals and treat disorders affecting the brain.
-
Sangamo, Pfizer Partner on ALS Gene Therapy
Drug maker Pfizer Inc. is licensing and collaborating on a gene therapy technology from Sangamo Therapeutics Inc. to treat amyotrophic lateral sclerosis, or ALS, and a related neurodegenerative disease.
-
Biotechs Partner on HPV Cancer Immunotherapies
Biotechnology companies in the U.S. and the Netherlands are collaborating on treatments for cancers caused by a type of human papillomavirus, or HPV.
-
Survey: More Research Patents, Start-Ups in 2016
A survey of universities and other institutions shows the number of patent filings and new start-up companies resulting from federally-funded research climbed in 2016.
-
Infographic – Patenting Among Top Tech Companies
CB Insights compiled a recent research brief with a chart showing where the top five technology companies — Google, Amazon, Facebook, Apple, and Microsoft — are placing their bets with new patent applications.
-
Bayer Acquiring Therapeutic Peptides in $1.1B+ Deal
Bayer AG, the global drug maker and agricultural chemical company, is partnering with a Japanese biologics enterprise to discover a series of peptides for therapies.
-
Biotech Licenses Mayo Clinic Microbiome Research
A biotechnology company developing therapies with specialized gut microbes is licensing research from the Mayo Clinic on these microbes’ effects with autoimmune diseases.
-
Zymeworks, Janssen in $1.45B Antibody Licensing Deal
Janssen Biotech, a division of drug maker Johnson & Johnson, is acquiring technologies that make it possible to create synthetic antibodies that hit multiple targets.
-
Sanofi Acquires Multiple Sclerosis Drug in $800M Deal
Drug maker Sanofi is licensing a drug candidate from Principia Biopharma Inc. designed to treat multiple sclerosis, an autoimmune condition affecting the brain and nervous system.